Please wait while the transcript is being prepared...
0:00
E. MICHAEL LEWIECKI:
Hello, this is Mike Lewiecki.
I'm talking to you today
about new and emerging
treatments for osteoporosis.
I'm director of New Mexico Clinical
Research and Osteoporosis Center
in Albuquerque, New Mexico,
and on the faculty of the University
of New Mexico School of Medicine.
0:21
This is my disclosure.
0:26
I'll be talking about
limitations of current therapy
for osteoporosis, new data
on available medications
for osteoporosis, recently approved
treatments, novel treatments
for intervention, investigational
agents, new delivery
systems, and strategies
to address unmet needs
in the care of osteoporosis.
0:51
These are approved
medications for osteoporosis
treatment and prevention.
We can classify drugs
at the present time
into those that reduce
bone remodeling,
typically called
antiresorptives, and those
that increase bone
remodeling, called
anabolics, or osteoanabolics.
As you can see, most drugs fall
into the antiresorptive category.
The biggest group
within that category
is the bisphosphonates,
alendronate, risedronate,
ibandronate, and zoledronic acid.
We have a selective estrogen
receptor modulator, raloxifene,
a rank ligand inhibitor, denosumab,
estrogen, nasal calcitonin,
and a combination of
estrogen and a SERM,
with conjugated estrogens
and bazedoxifene.
This is called a tissue
selective estrogen complex.
On the anabolic side,
we have one drug,
parathyroid hormone in the form
of teriparatide, which is PTH 1 to 34.
Strontium ranelate is a drug that
works by unclear mechanisms
and has sometimes been
said to have both antiresorptive
and anabolic properties.
The current treatments that
we have are pretty good.
